Bristol-Myers Squibb Co (NYSE:BMY) traded at $46.89 at last check on current trade day and made a downward move of -2.67% on its previous day’s price.
Bristol-Myers Squibb Co has a market cap of $95.43 billion and is expected to release its quarterly earnings report in June. With its Forward Dividend at 2.44 and a yield of 5.20%, the company’s investors could be anxious for the BMY stock to gain ahead of the earnings release.
On the other hand, looking at the outlook for the BMY stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 50% Sell.
Based on estimates by 14 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 9 have rated the Bristol-Myers Squibb Co (BMY) stock as a Hold, while 5 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the BMY stock currently stands at 0.24, and the most recent price level today is -3.73% off its SMA20 and -13.99% from its 50-day simple moving average. The RSI (14) is pointing at 35.94 while the volatility over the past week is 3.40% and jumps to 3.04% over the past one month. The beta value is 0.39, while the average true range (ATR) is currently pointing at 1.69. The average price target for the stock over the next 12 months is $66.5, with the estimates having a low of $65 and a high of $68. These price ends are -38.62% and -45.02% off the today’s price level respectively, although investors could be excited at the prospect of a -41.82% if the BMY share price touches on the median price of $66.5.
